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ABSTRACT Insoluble protein fibrils resulting from the
self-assembly of a conformational intermediate are implicated
as the causative agent in several severe human amyloid
diseases, including Alzheimer’s disease, familial amyloid poly-
neuropathy, and senile systemic amyloidosis. The latter two
diseases are associated with transthyretin (TTR) amyloid
fibrils, which appear to form in the acidic partial denaturing
environment of the lysosome. Here we demonstrate that
f lufenamic acid (Flu) inhibits the conformational changes of
TTR associated with amyloid fibril formation. The crystal
structure of TTR complexed with Flu demonstrates that Flu
mediates intersubunit hydrophobic interactions and intersub-
unit hydrogen bonds that stabilize the normal tetrameric fold
of TTR. A small-molecule inhibitor that stabilizes the normal
conformation of a protein is desirable as a possible approach
to treat amyloid diseases. Molecules such as Flu also provide
the means to rigorously test the amyloid hypothesis, i.e., the
apparent causative role of amyloid fibrils in amyloid disease.
The accumulation of insoluble protein fibrils in human tissue
is a common feature of neurodegenerative disease (1–3). In
many cases the protein’s native conformation is destabilized by
a genetic mutation or other environmental factors, typically
resulting in a b-sheet-rich conformational intermediate (4, 5).
These intermediates self-assemble into amyloid fibrils, such as
the fibrils found in patients with the transthyretin (TTR)-
associated amyloid diseases familial amyloid polyneuropathy
(FAP) and senile systemic amyloidosis (SSA) (6, 7). Trans-
thyretin is found in plasma and cerebrospinal f luid and is
composed of four identical 127-amino acid b-sheet-rich sub-
units. The tetrameric structure binds and transports thyroxine
(T4) and the retinol binding protein (8, 9). X-ray studies of
TTR show two funnel-shaped binding sites for T4, each
defined by a dimer–dimer interface (8, 10). In plasma, only
10–15% of TTR has T4 bound to it (Kas of 108 and 106 M21,
negative cooperativity), because thyroxine binding globulin is
the major thyroxine carrier (Ka 5 6 3 109 M21) (11). However,
in the cerebrospinal f luid, TTR is the main carrier of T4, with
75% of TTR binding T4 (12). Previous biophysical studies
demonstrated that the mechanism of TTR amyloid fibril
formation requires tetramer dissociation to a monomeric
conformational intermediate (6, 7). This conformational in-
termediate, generated under conditions simulating the pH of
a lysosome (5.5 6 0.5), self-assembles, affording amyloid fibrils
(lysosomes are intracellular organelles important for biopoly-
mer degradation and implicated in amyloid fibril formation)
(13, 14). Based on fiber diffraction and cryoelectron micros-
copy studies, the generated amyloid fibril is 130 Å in diameter
and is made up of four parallel protofilaments oriented in a
square section array, each having an apparent cross-b-helical
structure (15).
In heterozygous individuals with FAP, TTR amyloid fibrils
deposit in a variety of tissues, but generally not in the brain (16,
17). Amyloid isolated from FAP patients is composed primar-
ily of variant TTR, implying that the variant subunits are less
stable in their tetrameric form and therefore more amyloido-
genic than wild-type TTR. The age of onset of FAP appears
to be directly correlated to both the destabilizing effect of a
given mutation on TTR tetramer stability and the increased
rate of denaturation to the monomeric amyloidogenic inter-
mediate (Fig. 1, Inset) (18–20). FAP results in several severe
and often debilitating conditions by virtue of the neurotoxicity
of amyloid and/or its ability to physically interfere with normal
organ function (16, 21). Recent studies indicate that amyloid-
osis caused by the V122I TTR mutation, present in 2.2% of the
African American population, is associated with late-onset
heart disease in this population (22). Wild-type TTR fibrils are
thought to be the disease-causing agent in SSA in patients
typically .80 years of age (23). In SSA, it is not clear whether
fibril formation accumulates over time or rapidly, after a
triggering event. SSA is life-threatening in cases of cardiac
infiltration (16).
We recently reported that thyroid hormone and derivatives
thereof (e.g., 2,4,6-triiodophenol) strongly stabilize the normal
native conformation of TTR and inhibit wild-type, V30M, and
L55P amyloid formation under partially denaturing conditions
simulating lysosomal acidity (24). The ligand-induced inhibi-
tion of TTR fibril formation may also operate in vivo, as
thyroid-hormone binding to TTR in the cerebrospinal f luid
apparently stabilizes TTR against fibril formation in the brain
(24). Because thyroid-like molecules are undesirable as amy-
loid inhibitors (owing to their hormonal activity), we have set
out to identify novel small-molecule inhibitors.
EXPERIMENTAL METHODS
Fibril Formation Assay. Wild-type and variant TTR (L55P
and V30M) were purified from an Escherichia coli expression
system described previously (18, 19). Concentrated stock so-
lutions of flufenamic acid (Flu) were prepared by dissolving
the compounds in dimethyl sulfoxide. The stationary amyloid
fibril inhibition assay described previously (7, 24) was used
here . Briefly, a series of Eppendorf tubes filled with 200 mM
sodium acetate-buffered 100 mM KCl solutions (0.5 ml)
containing 5 ml of different concentrations of Flu were pre-
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pared at the desired pH. One-half ml of a 0.4 mg/ml TTR stock
solution in 10 mM phosphate (pH 7.6), 100 mM KCl, and 1 mM
EDTA was then added to the buffered inhibitor solution in
each Eppendorf tube to obtain a final TTR concentration of
0.2 mg/ml. In addition, two control samples containing TTR
with no inhibitor as well as Flu with no TTR were also
evaluated. All solutions were incubated while motionless at
37°C for 72 h, and the extent of fibril formation was measured
by OD at 330 nm and by using a quantitative Congo red binding
assay; both assays were described in detail previously (7, 24).
Preincubation of Flu with TTR before shifting the pH to
amyloid-forming conditions exhibited strictly analogous results,
implying the on rate for Flu binding to TTR is greater than the
rate of denaturation to the amyloidogenic intermediate.
Ultracentrifugation Studies. The effect of Flu on the qua-
ternary-structure stability of wild-type TTR was evaluated by
sedimentation velocity and sedimentation equilibrium ultra-
centrifugation methods using a temperature-controlled Beck-
man XL-I analytical ultracentrifuge equipped with an An60Ti
rotor and photoelectric scanner. TTR samples in the presence
or absence of 10.8 mM Flu were loaded into a double-sector
cell and evaluated at 235 nm as described (24).
Isothermal Titration Calorimetry (ITC). An isothermal
titration of a 500 mM solution of Flu (in 10 mM phosphate, pH
7.6/100 mM KCl/1 mM EDTA) into a 20 mM TTR solution (in
10 mM phosphate, pH 7.6/100 mM KCl/1 mM EDTA) using an
initial 2-ml injection followed by 24 10-ml injections at 25°C was
performed. Integration of the thermogram and subtraction of
the blank gives a binding isotherm that fits best to a model of
two identical interacting sites demonstrating negative cooper-
ativity. The data was fit by using four variables, K1, DH1, K2 and
DH2 using the ITC data analysis in ORIGIN version 2.3 (Mi-
crocal Software, Northampton, MD).
Crystallization. Crystals of TTR were grown by using the
hanging-drop vapor diffusion method from solutions of 5
mg/ml protein (in 100 mM KCl/100 mM phosphate, pH 7.4/1
M ammonium sulfate) equilibrated against 2 M ammonium
sulfate. To prepare the TTR-drug complex, crystals were
soaked for 5 wk with a 10-fold molar excess of Flu to ensure
full saturation of both binding sites.
Structure Determination. X-ray data for the apo- and com-
plexed crystal forms of TTR were collected on a DIP2030
imaging plate system (MAC Science, Yokohama, Japan). The
crystals were isomorphous with unit-cell dimensions of a 5 43.2
Å, b 5 85.3 Å, and c 5 64.5 Å. They belong to the space group
P21212 and contain one-half of the homotetramer in the asym-
metric unit. Data were reduced with DENZO and SCALEPACK (25).
The protein coordinates from the TTR–bromoflavone complex
(Protein Data Bank accession no. 1THC) were used as a starting
model for the initial refinement of the native structure using
molecular dynamics and energy minimization by using the pro-
gram XPLOR (26). Simulated annealing and individual tempera-
ture factor refinement provided a model which was used to phase
a ‘‘complex2native’’ difference-Fourier map. In the resulting
map, Flu could be located with peak heights of 10 srms in both
binding pockets of the TTR tetramer. Flu was found to bind in
two propeller-like conformations. The two minimum-energy
conformations of the drug (conformation trans: F1(C1-C6-N-
C19) 5 14° and F2(C6-N-C19-C29) 5 16°; conformation cis:
F1(C1-C6-N-C19) 5 14°/F2(C6-N-C192C29) 5 2168°) calcu-
lated by the program INSIGHT (BIOSYM INSIGHT II, Molecular
Simulations, Waltham, MA) were in good agreement with the
initial uFo, complexu 2 uFo, apou Fapo maps and were used as an initial
model in the crystallographic refinement. The molecular confor-
mations representing a mirror image of these two conformations
with identical formation energies did not match the observed
FIG. 1. Inhibiting amyloid formation. The extent of TTR amyloid fibril formation (37°C) in the absence and presence of various concentrations
of Flu probed by OD measurements at 330 nm (shown) and by quantitative Congo red binding (not shown, data virtually identical) (24). The
inhibition of wild-type (pH 4.4), V30M (pH 5.0), and L55P (pH 5.0) TTR by variable concentrations of Flu are shown with the errors associated
with these measurements. The pHs chosen are those associated with maximal amyloid fibril formation. The table (Inset) provides additional
information including pHm, the pH midpoint of the tetramer monomer equilibrium, and the IC50, the concentration of Flu required for reduction
of amyloid fibril formation to 50% of its maximum value.
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density maps. Because of the twofold crystallographic axis along
the binding channel, a statistical disorder model had to be
applied, giving rise to four binding conformations of Flu in each
of the two binding sites of TTR (cis, cis9, trans, trans9). After
several cycles of simulated annealing and subsequent positional
and temperature factor refinement, 56 water molecules were
placed into difference-Fourier maps. Both molecular conforma-
tions (trans F1/F2 5 10°/34°; cis F1/F2 5 21°/2151°) were in
good agreement with unbiased annealed 2 uFou 2 uFcu Fcalc omit
maps, phased in absence of the drug. All four binding confor-
mations of the drug are shown as an Inset to Fig. 3. Because of the
lack of interpretable electron densities in the final map, the nine
N-terminal and two C-terminal residues were not included in the
final model. A summary of the crystallographic analysis can be
found in Table 1.
RESULTS AND DISCUSSION
Compounds whose structures complement the known binding
site of TTR were screened as possible inhibitors by using
established amyloid fibril assays including a light-scattering
assay and a quantitative Congo red fibril-formation assay (7,
27). Active compounds were further evaluated by analytical
ultracentrifugation to demonstrate that the normal tetrameric
conformation of TTR was adopted in the presence of the
inhibitors under acidic conditions that, in the absence of
inhibitor, would normally result in tetramer dissociation and
the conformational changes leading to amyloid formation (24).
Screening allowed us to identify several bisarylamine inhibi-
tors including the nonsteroidal antiinflammatory drug Flu,
which binds and stabilizes the nonamyloidogenic tetramer.
Incubation of physiological concentrations of TTR (3.6 mM) at
pH 4.4 (the optimal pH for wild-type amyloid fibril formation)
results in the conversion of the majority of TTR ('60%) into
amyloid after 72 h in the absence, but not in the presence of
FIG. 2. Structure of the Flu–TTR complex.
Ribbon diagram of tetrameric TTR with Flu as
computed with the program SETOR (32). The
two molecules of Flu, binding into the T4-
binding channels of TTR, are shown as a stick
model. Because of the twofold axes along the
binding channel (pointing from left to right in
the paper plane) a second symmetry-related
binding mode is present for both molecules
(statistic disorder). For clarity, a second mo-
lecular conformation of the Flu that is also in
agreement with the crystallographic data is
not displayed. Each monomer of TTR consists
of 127 amino acid residues that form two
stacked sheets, each containing four antipar-
allel b-strands (sheet I: HGAD; sheet II:
FEBC). The subunits are linked by hydrogen
bonds within the b-strands H and F with the
equivalent strands H9 and F9 in the second
subunit. These interactions extend the two
four-stranded b-sheets into eight-stranded
b-sheets in the dimer. Two of these dimers are
sandwiched on top of one another to assemble
the tetrameric molecule through interactions
of the AB and GH loops. The opposition of the
convex faces of the b-sheets I and I9 (because
of the right-hand twist of their b-strands) gives
the funnel-like depressions, representing the
two Flu-binding channels.
Table 1. Summary of crystallographic analysis
Apo TTRpFlu
Resolution, Å 20–2.0 20–2.0
Reflections,
measuredyunique 64,327y16,218 86,716y16,664
Completeness, %
overallyouter shell 96.7y84.0 99.6y99.4
Rsym, % overallyouter shell 5.2y11.7 6.3y28.5
Iys1 13.9 10.6
Refinement statistics
Resolution, Å 6.0–2.0 8.0–2.0
RfactoryRfree, % 18.3y24.4 18.9y25.1
rmsd bond length, Å 0.015 0.016
rmsd bond angles, degrees 2.011 2.037
Rsym 5 ¥ uI 2 ^I&uy¥ ^I&, where I is the observed intensity, and ^I&
is the average intensity of multiple observations of symmetry-related
reflections. Rfactor ¥ uFo 2 Fcuy¥Fo where Fo and Fc are observed and
calculated structure factor amplitudes, respectively. Rfree is calculated
for a randomly chosen subset of 10% of the reflections. rmsd is the root
mean squared deviation from ideal geometry.
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3 equivalents (10.8 mM) of Flu (Fig. 1). In the presence of Flu,
the sedimentation equilibrium and velocity data fit to a single
ideal species model corresponding to nonamyloidogenic tet-
rameric TTR (54 kDa), demonstrating that the ligand inhibits
fibril formation by stabilizing the normal fold against the
pathogenic conformational changes (24). Two equivalents of
Flu bind to the wild-type TTR tetramer (pH 7.6) with negative
cooperativity (Kd1 5 30 6 14 nM, Kd2 5 255 6 97 nM) as
measured by ITC. The observed dissociation constants for the
FAP variants V30M (Kd1 5 41 6 10 nM, Kd2 5 320 6 125 nM),
and L55P TTR (Kd1 5 74 6 16 nM, Kd2 5 682 6 137 nM) are
slightly higher. However, the Kds are low enough in every case
to saturate both binding sites in TTR when the Flu concen-
tration equals 10.8 mM, i.e., three times the physiological TTR
concentration (3.6 mM), ensuring that there is enough drug to
bind to both binding sites. It is not yet clear whether one or both
binding sites in TTR must be occupied to achieve complete
amyloid fibril inhibition. The conversion of 30% of a 3.6-mM
solution of TTR into amyloid fibrils (70% inhibition, 3.6 mM Flu,
pH 4.4) when TTR has one of the two ligand-binding sites
occupied suggest that complete inhibition requires occupancy of
both sites. However, this interpretation assumes that the disso-
ciation constant does not increase appreciably with a decrease in
pH, which remains to be demonstrated.
To further understand the structural basis for the efficacy of
Flu as a fibril inhibitor, co-crystals of Flu bound to TTR were
produced, and the crystal structure of the binary complex was
solved by using molecular-replacement methods and was re-
fined to a resolution of 2.0 Å (Table 1). As in the TTR–T4
complex, two molecules of Flu were bound deep into the
central hormone-binding funnel of the TTR tetramer, Fig. 2.
In each binding site, four different binding conformations of
Flu were found with approximately equal occupancy (Fig. 3).
FIG. 3. (Left) Flu–TTR interactions. Ribbon diagram of the tetrameric TTR with Flu showing a closeup of one of the two funnel-shaped binding
cavities computed by the program SETOR (32). The binding site is formed by two adjacent TTR monomers related by a twofold axis of symmetry (from
left to right in the paper plane). Residues Ser-117, Thr-119, and Lys-15, which are displaced on binding of Flu, are highlighted. For clarity, only the trans
conformation of Flu is shown with its symmetry mate. Insets show all four observed binding conformations (the molecular conformations cis and trans
with the symmetry related binding modes cis9 and trans9). (Right) TTR conformational changes mediated by Flu binding. A stick model of the Flu binding
site as computed by O (33). Only residues from one subunit of TTR that align the binding cavity are displayed, with their 2 uFou 2 uFcu Fcalc density in
cyan. Flu is shown in all four of its binding modes. Because of the twofold-symmetry axis (from left to right in paper plane) both molecular conformations
of Flu fit in two symmetry-related binding modes into the final 2 uFou 2 uFcu Fcalc in green. Oxygen atoms are red, nitrogen atoms are blue, fluorine atoms
are green, and carbon atoms are shown in white and cyan, respectively. The protein–ligand interactions are described in the text.
Table 2. Interaction distances in the complex of TTR with Flu
Ligand atom Protein atom
Distance, Å
cis trans
F1 Ser-117 O 3.22 3.38*
Ser-117 Cb 2.92 2.83*
Leu-110 Cb 3.30 3.52*
F2 Thr-119 Cb 3.23 3.12*
Leu-110 Cd2 3.11* 3.18
F3 Ser-117 O 3.57 3.46*
Ala-109 C 3.83 3.72*
Ala-108 O 3.31 3.43*
Ala-108 Cb 3.68 3.87*
C49 Leu-110 Cb 3.94
C69 Ala-108 Cb 3.49* 3.59
C3 Val-121 Cg2 3.95
Thr-106 Cg2 3.76 3.49
Ala-108 Cb 3.77
C4 Ala-108 Cb 3.23 3.39
Val-121 Cg2 3.88 3.57
Thr-119 Cg2 3.69 3.91
Leu-17 Cd1 3.33* 3.55*
C5 Ala-108 Cb 3.37 3.18
Leu-17 Cd1 2.87* 2.96*
Thr-119 Cg2 3.60 3.51
C6 Leu-17 Cd1 3.34* 3.31*
O1 Lys-15 N 2.88 2.96
Lys-15 N 3.72* 3.57*
The values for both molecular conformations of Flu have been
averaged over the two symmetry-related monomers and are listed in
Å. Both molecular conformations differ in their dihedral angles along
the aryl–N–aryl bonds (trans F1yF2 5 10°y34°; cis F1yF2 5 21°y
2151°). Distances marked with an asterisk reflect interactions of the
drug with the second of the two monomers forming the binding cavity.
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The refined structure of the TTR–Flu binary complex
clearly defines the molecular interactions that allow the drug
to bind to TTR. In all four binding modes, Flu interacts with
residues of two adjacent TTR molecules, thus mediating
several intersubunit interactions. The CF3 substituent occupies
the innermost halogen-binding pocket, interacting with Ser-
117, Thr-119, Leu-110, and Ala-108, providing van der Waals
contacts (Fig. 3). For complex interaction distances see Table
2. The biphenyl system of Flu is found in a low-energy
propeller-like conformation in a hydrophobic patch of the T4
binding site between the residues Leu-17, Thr-106, Ala-108,
Thr-119, and Val-121. Finally, the carboxylate group on the
outer phenyl ring is placed at the entrance of the funnel-shaped
binding pocket, forming electrostatic interactions with the side
chains of the Lys-15 residues from opposing subunits.
The binding of Flu also induces conformational changes in
TTR that appear to have a stabilizing effect on the TTR
tetramer. Specifically, the side chains of Ser-117 and Thr-119
rearrange to facilitate additional hydrogen bonding between
the subunits of the tetramer (Fig. 3). In the ligand-free
tetramer, the side chains of all four Ser-117 residues are
pointing toward the two T4 binding cavities interacting with
bulk H2O. Binding of Flu, however, causes the side chains of
the Ser-117 residues of all four monomers to rotate about 120°,
leading to the formation of two nonsolvated hydrogen bonds
between the Ser-117 residues on adjacent subunits (four new
hydrogen bonds per tetramer). A similar ligand-induced con-
formational change of the Thr-119 side chain leads to the
formation of a hydrogen bond to an ordered water molecule,
which in turn is hydrogen bonded to the carbonyl oxygen of
Asp-18 of an adjacent subunit of the tetramer. In summary, Flu
binding appears to initiate intersubunit hydrogen bonding and
hydrophobic interactions, the latter being mediated by the
arylamine substructure of Flu. These intermediates stabilize
the normal fold of TTR against the pH-mediated dissociation
and conformational changes associated with amyloid fibril
formation.
These data demonstrate that Flu binds with high affinity to
wild-type TTR and with modest affinity to L55P and V30M
TTR, stabilizing the normally folded state against the pH-
induced conformational changes that lead to amyloid fibril
formation. Because TTR transports only 10–15% of T4 in
plasma (thyroid-binding globulin being the main T4 carrier),
inhibitor binding to TTR should not perturb normal thyroid
metabolism. This hypothesis is further supported by the small
effect that the TTR knockout has on T4 metabolism in mice
(28). Unlike other inhibitors we have identified that bind to a
variety of plasma proteins (e.g., albumin), Flu exhibits strong
binding selectivity for TTR (29). In addition, Flu exhibits
nonsteroidal antiinflammatory activity, which is very interest-
ing considering the promising effect exhibited by some non-
steroidal antiinflammatory drugs in delaying the onset of
Alzheimer’s disease (30). However, the role of inflammation
in SSA and FAP pathology is less clear. Based on the structural
data outlined herein and emerging crystallographic data with
other inhibitors, it is likely that success will be realized in
designing novel compounds that bind to TTR with high affinity
and prevent amyloid formation by stabilization of the normally
folded form of this potentially amyloidogenic protein.
A small-molecule therapeutic strategy is highly desirable in
comparison to the surgical strategy currently used to treat
eligible FAP patients, where the FAP-associated TTR gene is
replaced by the wild-type gene via liver transplantation (31).
Currently, there is no effective treatment for SSA, which
should be amenable to management by using the approach
described within. Perhaps most importantly, a small-molecule
inhibitor strategy makes it practical to further evaluate the
amyloid hypothesis. Even though there is an overwhelming
amount of circumstantial evidence favoring the amyloid hy-
pothesis, it remains to be demonstrated that the inhibition of
fibrils will prevent disease onset.
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